Projects
Excitation-inhibition imbalance in autism-epilepsy comorbidity, a preclinical and clinical study KU Leuven
Preclinical progression of novel anti-trypanosomal nucleoside 'lead' series towards veterinary application. University of Antwerp
Development of a cutting-edge service platform for in vivo preclinical testing of drug candidates able to treat chronic kidney disease and its associated co-morbidities. University of Antwerp
Development and integrated use of novel preclinical models to assess intestinal absorption and hepatic elimination in order to achieve accelerated biopharmaceutical drug profiling. KU Leuven
FAPi-PLA: Accelerating the preclinical development of Fibroblast-activation protein (FAP)-targeted theranostics through a highly interdisciplinary in vitro platform: University of Antwerp
RECONNECT – preclinical studies to rescue sequelae of exposure to chemotherapeutics KU Leuven
Implantable Dural Venous Sinus Access Device (DVSAD), a preclinical assessment of human prototypes. Ghent University
Our objective is to bring the DVSAD to the point that it can be licensed to a third party for commercialisation. The 3 main phases in this trajectory would be prototyping/Intellectual Property (IP), preclinical and clinical testing. The prototyping and IP phases have been covered in the initial StarTT-project. Evaluation and refinement of the prototypes have been the subject of the Advanced-project. This first evaluation led to several new ...
Creation of a preclinical platform at the UA for testing novel therapeutic approaches against ocular surface diseases. University of Antwerp
CoVAX-PreC – Preclinical evaluation of a potent COVID-19 vaccine candidate toward an accelerated clinical development KU Leuven
Within the group of Prof. Johan Neyts, the vaccine team (under the scientific lead of Dr. Kai Dallmeier) developed a promising COVID-19 vaccine candidate. This live-attenuated vaccine shows great promise in animal models. By this CoVax-PreC project we want to study the longevity of the triggered immunity as well as the potential of the vaccine to prevent SARS-CoV-2 transmission within a population (by means of a hamster transmission model). ...